top of page

What Is Tesamorelin?

 

Tesamorelin is a synthetic growth hormone–releasing hormone (GHRH) analogue used to stimulate the body’s natural production of growth hormone. It is approved in certain regions for the reduction of excess abdominal fat in adults and is also studied for metabolic and body-composition effects.

​

Unlike GLP-1 or amylin-based therapies, tesamorelin works through the growth hormone / IGF-1 pathway, influencing how the body uses fat and energy.

 

How Does Tesamorelin Work?

 

Tesamorelin acts on the pituitary gland to increase natural growth hormone release:

 

  • GHRH receptors — Stimulate pulsatile growth hormone secretion.

  • Growth hormone pathway — Increases IGF-1 levels, which can influence fat metabolism.

  • Body composition regulation — May help reduce visceral abdominal fat while supporting metabolic function.

 

By enhancing the body’s own hormone signaling rather than replacing growth hormone directly, tesamorelin aims to produce more physiologic effects.

 

Potential Benefits?

 

  • Reduction in visceral abdominal fat in some patients

  • Changes in body composition

  • Support for metabolic health markers

  • Possible improvements in lipid profiles in certain populations

 

Side Effects and Safety Considerations?

 

As with hormone-modulating therapies, reported side effects may include:

 

  • Injection-site reactions

  • Joint or muscle discomfort

  • Fluid retention or swelling

  • Headache or mild nausea

  • Changes in blood sugar in some individuals

 

Recommended Dosing Schedule?

 

Estimated Half-Life is Approximately 20–30 minutes in circulation.

 

Why it matters:
• Tesamorelin is cleared from the bloodstream relatively quickly
• Typically requires daily dosing rather than weekly dosing
• Effects occur through stimulation of natural hormone release rather than long drug persistence

 

Steady state refers to when hormone responses become consistent with regular dosing.
Because tesamorelin works by triggering growth hormone pulses rather than remaining in the body for days, traditional long “steady state accumulation” seen with weekly peptides does not apply in the same way.

Instead, consistent daily use allows IGF-1 levels and metabolic effects to stabilize over time — often within several weeks of regular dosing.

 

Tesamorelin is generally introduced at a consistent 1mg daily dose rather than large step-wise escalations. Any adjustments should be made gradually to help maintain tolerability.

 

Dose increases are not always necessary. If you are achieving desired body-composition or metabolic outcomes without significant negative side effects, maintaining a stable dose may be appropriate rather than increasing further.

​

Our pens have and adjustable dosing range of 1-4mg, and a shelf life of 12-18 month.

bottom of page